Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 153 Jul 18 – Oct 15, 2026
- Disclosed funding
- $5.2B 123 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| RN Rege Nephro CoCompany profile Developing innovative therapies and medical technologies for patients with kidney diseases who currently have limited treatment options Developing innovative therapies and medical technologies for patients with kidney diseases who currently have limited treatment options | $10.6M | Series CSeries C+ | Biotech | Japan | Investors | |
| ET Estrigenix TherapeuticsCompany profile Developing selective estrogen receptor-beta therapeutics for women's health and neurodegenerative diseases Developing selective estrogen receptor-beta therapeutics for women's health and neurodegenerative diseases | $2M | Seed | Biotech | United States | Investors | |
| BP Brenus PharmaCompany profile Develops an off-the-shelf in vivo immunotherapy platform for solid tumors Develops an off-the-shelf in vivo immunotherapy platform for solid tumors | €11M | Series A | Biotech | France | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jul 18, 2026
- 1Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
10rounds0led - 2RA Capital Management
Circle Pharma, Inc., Solstice Oncology, Superluminal Medicines
8rounds2led - 3Y Combinator (YC)
Molagri, Sensible Biotechnologies, WonderTx
6rounds0led - 4Catalio Capital Management
BigHat Biosciences, Basecamp Research, Enveda
6rounds2led - 5Oxford Science Enterprises
OMass Therapeutics, ReEmerge, Inc., Vivid Dx
5rounds0led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.